Multinational drug-maker GlaxoSmithKline Pharmaceuticals Ltd. has decided to invest more to support its growth. The leading pharmaceutical company is expected to increase its expenses towards its sales growth and promotional efforts.

However, the company's forth quarter financial report has been quite impressive and it has managed to register reasonable amount of net profit as well as net revenue. The company has seen a remarkable 28% growth in the net sales growth for the first quarter of 2010.

According to Senior Executive Director of GSK's Pharma, Mr. Mehernosh Kapadia, now the company is looking forward to improve its supportive field-force and promotional efforts for the coming years. The net sales of the company have to be taken care of simultaneously.

He has also informed that the company has several new products to launch this financial year. These upcoming products include vaccines, Infanrix-Hexa (a six-component vaccine) and pneumococcal vaccine Synflorix, couple of cancer drugs and a blood-platelet boosting drug. Hence the pharmaceutical company is focusing on its promotional events so that it can push the sales in different sectors.